Correction to

Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG) (Journal of Neuro-Oncology, (2019), 143, 3, (573-581), 10.1007/s11060-019-03194-z)

Kurt Jaeckle, S. K. Anderson, Erin L. Twohy, Jesse G. Dixon, Caterina Giannini, Robert Jenkins, Merrill J. Egorin, Jann N. Sarkaria, Paul D. Brown, P. J. Flynn, John Schwerkoske, Jan C. Buckner, Evanthia Galanis

Research output: Contribution to journalComment/debate

Abstract

The last author's first name was truncated in the initial online publication. The original article has been corrected.

Original languageEnglish (US)
Number of pages1
JournalJournal of Neuro-Oncology
Volume143
Issue number3
DOIs
StatePublished - Jul 1 2019

Fingerprint

Oligodendroglioma
Astrocytoma
Names
Publications
Neoplasms
Imatinib Mesylate

All Science Journal Classification (ASJC) codes

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Cite this

Jaeckle, Kurt ; Anderson, S. K. ; Twohy, Erin L. ; Dixon, Jesse G. ; Giannini, Caterina ; Jenkins, Robert ; Egorin, Merrill J. ; Sarkaria, Jann N. ; Brown, Paul D. ; Flynn, P. J. ; Schwerkoske, John ; Buckner, Jan C. ; Galanis, Evanthia. / Correction to : Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG) (Journal of Neuro-Oncology, (2019), 143, 3, (573-581), 10.1007/s11060-019-03194-z). In: Journal of Neuro-Oncology. 2019 ; Vol. 143, No. 3.
@article{bcb080dcfd334edbb64ee0dfb8a85210,
title = "Correction to: Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG) (Journal of Neuro-Oncology, (2019), 143, 3, (573-581), 10.1007/s11060-019-03194-z)",
abstract = "The last author's first name was truncated in the initial online publication. The original article has been corrected.",
author = "Kurt Jaeckle and Anderson, {S. K.} and Twohy, {Erin L.} and Dixon, {Jesse G.} and Caterina Giannini and Robert Jenkins and Egorin, {Merrill J.} and Sarkaria, {Jann N.} and Brown, {Paul D.} and Flynn, {P. J.} and John Schwerkoske and Buckner, {Jan C.} and Evanthia Galanis",
year = "2019",
month = "7",
day = "1",
doi = "10.1007/s11060-019-03201-3",
language = "English (US)",
volume = "143",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "3",

}

Correction to : Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG) (Journal of Neuro-Oncology, (2019), 143, 3, (573-581), 10.1007/s11060-019-03194-z). / Jaeckle, Kurt; Anderson, S. K.; Twohy, Erin L.; Dixon, Jesse G.; Giannini, Caterina; Jenkins, Robert; Egorin, Merrill J.; Sarkaria, Jann N.; Brown, Paul D.; Flynn, P. J.; Schwerkoske, John; Buckner, Jan C.; Galanis, Evanthia.

In: Journal of Neuro-Oncology, Vol. 143, No. 3, 01.07.2019.

Research output: Contribution to journalComment/debate

TY - JOUR

T1 - Correction to

T2 - Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG) (Journal of Neuro-Oncology, (2019), 143, 3, (573-581), 10.1007/s11060-019-03194-z)

AU - Jaeckle, Kurt

AU - Anderson, S. K.

AU - Twohy, Erin L.

AU - Dixon, Jesse G.

AU - Giannini, Caterina

AU - Jenkins, Robert

AU - Egorin, Merrill J.

AU - Sarkaria, Jann N.

AU - Brown, Paul D.

AU - Flynn, P. J.

AU - Schwerkoske, John

AU - Buckner, Jan C.

AU - Galanis, Evanthia

PY - 2019/7/1

Y1 - 2019/7/1

N2 - The last author's first name was truncated in the initial online publication. The original article has been corrected.

AB - The last author's first name was truncated in the initial online publication. The original article has been corrected.

UR - http://www.scopus.com/inward/record.url?scp=85067028011&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067028011&partnerID=8YFLogxK

U2 - 10.1007/s11060-019-03201-3

DO - 10.1007/s11060-019-03201-3

M3 - Comment/debate

VL - 143

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 3

ER -